Clinical trials
NPC clinical trials
Below are recruiting npc clinical trials, each written for real people, not researchers. We’re tracking 76 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06472713RecruitingPhase 2
Liposomal mitoxantrone with immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Zhuhai, GuangdongAges 18–70 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06611150RecruitingPhase 1
Chemo and radiation for advanced nasopharyngeal cancer
This trial tests whether a specific chemotherapy drug (nab-paclitaxel) given along with targeted radiation therapy can help people with stage III or IVa nasopharyngeal cancer. The goal is to improve treatment outcomes while managing side effects.
Guangzhou, GuangdongAges 18–70 - NCT06657690RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after immunotherapy
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
Zhuhai, GuangzhouAges 18–70 - NCT06733948RecruitingPhase 2
Dental stent to protect taste during NPC radiation
This trial tests whether a custom-fitted dental stent (like a mouthguard) can help protect your sense of taste during radiation and chemotherapy for nasopharyngeal cancer. If you qualify, you'll receive either standard care or the stent, and your taste changes will be tracked.
SingaporeAges 21–100 - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT06752239RecruitingPhase 3
Optimizing radiation to protect thyroid in nasopharyngeal cancer
This trial tests a way to adjust radiation therapy to better protect the thyroid gland during treatment for nasopharyngeal carcinoma. It aims to reduce thyroid damage while still effectively treating the cancer.
Nanchang, JiangxiAges 18–70 - NCT06763289Recruiting
Comparing new blood tests for early nasopharyngeal cancer
This study is testing if a new blood test can help find nasopharyngeal cancer early. It compares different methods to see which works best. This could help people get diagnosed and treated sooner.
Guangzhou, GuangdongAges 40–75 - NCT06796270Recruiting
Short-course radiation for nasopharyngeal cancer
This trial tests a shorter course of radiation therapy for people with nasopharyngeal cancer, a type of head and neck cancer. The goal is to see if a hypofractionated (fewer, larger doses) approach is safe and effective.
Haikou, HainanAges 18–75 - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT06870435Recruiting
Screening for nasopharyngeal cancer with blood tests
This study compares three different blood tests to see which works best for spotting nasopharyngeal cancer early in people at higher risk. If you live in certain areas of China, you may be able to join.
Zhuhai, GuangdongAges 30–69 - NCT06909799Recruiting
NAC to prevent lung damage after TB treatment
This trial tests if taking N-acetylcysteine (NAC) alongside standard TB treatment can help prevent long-term lung problems after tuberculosis. It is for people with moderate to severe TB who already have some reduced lung function.
Fajara, The GambiaAges 18–65 - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT07085988RecruitingPhase 2
Nutrition help for nasopharyngeal cancer patients on chemoradiation
This trial tests if special nutritional management during concurrent chemoradiotherapy can improve outcomes for people with nasopharyngeal cancer. If you are getting both chemotherapy and radiation as your main treatment, this study may help you maintain better nutrition.
Nanchang, JiangxiAges 18 years+ - NCT07188584RecruitingPhase 3
Smaller radiation vs. standard after chemo-immunotherapy for advanced nasopharyngeal cancer
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
ZhuhaiAges 18–70 - NCT07201337RecruitingPhase 3
Lower vs standard radiation dose for low-risk nasopharyngeal cancer
This trial tests if a slightly lower dose of radiation can work just as well as the standard dose for patients with a certain type of nasopharyngeal cancer. The goal is to reduce side effects while keeping the cancer under control.
Dongguan, GuangdongAges 18–70 - NCT07236190RecruitingPhase 2
Using brain markers to test NPC-1 for Alzheimer's
This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.
Boston, MassachusettsAges 55 years+ - NCT07277764RecruitingPhase 2
Radiation and immunotherapy for returning nasopharyngeal cancer
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Nanchang, JiangxiAges 18–75 - NCT07327216RecruitingPhase 3
Comparing two inhalations for mouth sores from cancer treatment
This trial tests if an inhaled medication called Sapylin can prevent or reduce severe mouth sores caused by chemoradiation, compared to a standard steroid inhalation. It is for people with advanced nasopharyngeal cancer who have not yet started treatment.
Zhanjiang, GuangdongAges 18–75 - NCT07328841RecruitingPhase 3
Lower radiation dose study for advanced nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT07332247RecruitingPhase 2
Immunotherapy plus chemo then immediate vs selective re-radiation for advanced recurrent NPC
This trial is for people with nasopharyngeal cancer that has come back in the same area. It tests whether giving additional radiation right after chemo plus immunotherapy works better than waiting to see if more radiation is needed later.
Guangzhou, GuangdongAges 18–70 - NCT07340515RecruitingPhase 3
Proton vs standard radiation for advanced nasopharyngeal cancer
This trial is testing whether a newer, more precise type of radiation (proton therapy) works better than standard radiation (IMRT) for people with advanced nasopharyngeal cancer. It also includes chemotherapy and immunotherapy to see if the combination can improve outcomes.
Jinan, ShandongAges 18–70
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for npc?
- Yes. Clin2 currently lists 76 recruiting npc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a npc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a npc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.